{
  "title": "M21-1, Part V, Subpart iii, Chapter 2, Section A - Conditions of the Eyes",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014461/M21-1-Part-V-Subpart-iii-Chapter-2-Section-A-Conditions-of-the-Eyes",
  "content": "<--Previous Section\nNext Section-->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nBasic Rating Principles for Eye Conditions\n2\nCongenital and Developmental Defects and Refractive Error of the Eyes\n3\nOther Eye Conditions\n4\nExamples of Rating Decisions for Diplopia\n1\n.\nBasic Rating Principles for Eye Conditions\nIntroduction\nThis topic contains basic rating principles for eye conditions, including\nevaluating visual acuity\nmeasuring field of vision\nexamination requirements for diplopia\nevaluating diplopia with impairment of visual acuity or field\nconsidering impairments of both visual acuity and visual field\nincapacitating episodes of eye disease\nciting disease or injury in the diagnosis\nevaluating anatomical loss of one eye with inability to wear a prosthesis\nconsidering visual acuity in a non-service-connected (NSC) eye when the other eye is service-connected (SC)\n, and\nchanges in the eye rating schedule\n.\nChange Date\nJune 7, 2019\nV.iii.2.A.1.a\n.\nEvaluating Visual Acuity\nEvaluate central visual acuity on the basis of corrected distance vision with central fixation, even if a central scotoma is present.\nException\n:  Evaluate the visual acuity of the poorer eye using either its uncorrected or corrected visual acuity, whichever results in better combined visual acuity, when\nthe lens required to correct distance vision in the poorer eye differs by more than three diopters from the lens required to correct distance vision in the better eye\nthe difference is not due to congenital or developmental refractive error, and\neither the poorer eye or both eyes are service-connected (SC).\nReference\n:  For more information on evaluating eye disabilities based on visual acuity, see\n38 CFR 4.76\n.\nV.iii.2.A.1.b\n.\nMeasuring Field of Vision\nThe examining medical facility retains discretion in the exact method used to measure visual fields.  When visual field testing is required, the facility must use one of the following:\nGoldmann Bowl kinetic perimetry\nautomatic perimetry (Humphrey Model 750, Octopus Model 101), or\nlater versions of the Humphrey or Octopus machines with simulated Goldmann kinetic perimetry.\nNotes\n:\nFollow the guidelines in\nM21-1, Part IV, Subpart i, 3.B.1.a\nto determine when an examination report must contain visual field measurements.\nResults from visual field testing may be reported in chart or table format.  Inclusion of the Goldmann chart or equivalent charting is not a requirement in any circumstance.\nReferences\n:  For more information on\nvisual field standards, see\n38 CFR 4.77\n, and\nexaminations for visual impairment and specifically visual field, see\n38 CFR 4.77\n.\nV.iii.2.A.1.c\n.\nExamination Requirements for Diplopia\n38 CFR 4.78\nrequires use of Goldmann Bowl kinetic perimeter testing or the Tangent Screen for examination of muscle function.  The examiner must document the results of muscle function testing by identifying the quadrant(s) and range(s) of degrees in which diplopia exists.  Documentation on a Goldmann Perimeter Chart is\nnot\nrequired but is acceptable.\nA diagnosis of diplopia that reflects the disease or injury that is the cause of the diplopia must be of record.\nV.iii.2.A.1.d\n.\nEvaluating Diplopia With Impairment of Visual Acuity or Field\nWhen the affected field with diplopia extends beyond more than one quadrant or range of degrees, evaluate diplopia based on the quadrant and degree range that provides the higher (or highest) evaluation.  When diplopia exists in two separate areas of the same eye, increase the equivalent visual acuity under\n38 CFR 4.79, diagnostic code (DC) 6090\nto the next poorer level of visual acuity, but not to exceed 5/200.\nFollow the steps in the table below when assigning an evaluation to visual impairment when a claimant has both\ndiplopia, and\na ratable impairment of visual acuity or loss of visual field in either eye.\nStep\nAction\n1\nAssign a level of visual acuity for diplopia for only one eye under\n38 CFR 4.79, DC 6090\n.\n2\nFollow the instructions in the table below.\nIf the visual acuity level assignable for diplopia is …\nThen assign a level of corrected visual acuity for the poorer eye (or affected eye, if only one is SC) that is …\n20/70 or 20/100\none step poorer than it would otherwise warrant, not to exceed 5/200.\n20/200 or 15/200\ntwo steps poorer than it would otherwise warrant, not to exceed 5/200.\n5/200\nthree steps poorer than it would otherwise warrant, not to exceed 5/200.\n3\nDetermine the evaluation for visual impairment under\n38 CFR 4.79, DC 6065 or 6066\nby using the\nadjusted visual acuity of the poorer eye (or affected eye, if only one is SC), and\ncorrected visual acuity for the better eye (or visual acuity of 20/40 for the other eye, if only one eye is SC).\nExample\n:\nThe Veteran has an SC evaluation for diplopia.\nDiplopia in both eyes is in the 31 to 40 degree range of upward vision and in the 31 to 40 degree range of lateral vision.\nThe diplopia in the upward vision is equivalent to visual acuity of 20/40, while the diplopia in the lateral vision is equivalent to visual acuity of 20/70.\nResult\n:\nBased on\n38 CFR 4.78(b)(2) and (3)\n, the overall equivalent visual acuity for diplopia is 20/100, which is one step poorer than the diplopia (in this case, the lateral) that provides the higher evaluation.\nThe overall evaluation for diplopia is, therefore, 10 percent, based on visual acuity of 20/100 for one eye and 20/40 for the other eye (diplopia is only taken into consideration for one eye).\nNote\n:  Diplopia that is occasional or that is correctable with corrective lenses is evaluated at zero percent.\nReference\n:  For examples of rating decisions for diplopia, see\nM21-1, Part V, Subpart iii, 2.A.4\n.\nV.iii.2.A.1.e\n.\nConsidering Impairments of Both Visual Acuity and Visual Field\nWhen there are impairments of both visual acuity and visual field\ndetermine for each eye the percentage evaluation for visual acuity and for visual field loss (expressed as a level of visual acuity under\n38 CFR 4.79, DC 6080\n), and\ncombine the evaluations under\n38 CFR 4.25\n.\nThe combined evaluation for visual impairment can then be combined with any other disabilities that are present.\nSituation\n:\nCorrected visual acuity is 20/40 in the right eye and 20/70 in the left eye, warranting a 10-percent evaluation.\nVisual field loss in right eye is remaining field 38 degrees (equivalent to visual acuity 20/70) and loss in left eye is remaining field 28 degrees (equivalent to visual acuity 20/100), warranting a 30-percent evaluation.\nResult\n:  Under\n38 CFR 4.25\n, combine the 30-percent evaluation for visual field loss with the 10-percent evaluation for visual acuity, which results in a 40-percent combined evaluation for bilateral visual impairment.\nV.iii.2.A.1.f\n.\nIncapacitating Episodes of Eye Disease\nAn incapacitating episode, for the purpose of evaluating diseases of the eye, is a situation in which symptoms are severe enough to require a clinic visit to a provider specifically for treatment purposes.\nNotes\n:\nA clinic visit for diagnostic, monitoring, or screening purposes is not sufficient to satisfy the criteria for a clinic visit for treatment purposes.\nThe definition of incapacitating episode was updated effective with the May 13, 2018, revision to\n38 CFR 4.79\n.  This and other changes made in that update were not liberalizing changes.\nReference\n:  For more information on incapacitating episodes of diseases of the eye, as well as examples of treatment sufficient to meet the criteria for incapacitating episodes, see\n38 CFR 4.79\n,\nGeneral Rating Formula for Diseases of the Eye\n, Notes 1 and 2.\nV.iii.2.A.1.g\n.\nCiting Disease or Injury in the Diagnosis\nCite the actual disease, injury, or other basic condition as the diagnosis, rather than a mere citation of impaired visual acuity, field of vision, or motor efficiency.\nNote\n:  Actual pathology, other than refractive error, is required to support\nimpairment of visual acuity.  Impaired field of vision and impaired motor field function must be supported by actual appropriate pathology.\nV.iii.2.A.1.h\n.\nEvaluating Anatomical Loss of One Eye With Inability to Wear a Prosthesis\nWhen the evidence shows anatomical loss of one eye together with inability to wear a prosthesis, increase the evaluation for visual acuity under\n38 CFR 4.79, DC 6063\nby 10 percent.\nNotes\n:\nThe maximum evaluation for visual impairment of both eyes will not exceed 100 percent.\nAssignment of the 10-percent increase under\n38 CFR 4.79, DC 6063\nprecludes an evaluation under\n38 CFR 4.118, DC 7800\nbased on gross distortion or asymmetry of an eye.  A separate evaluation may be assigned under\n38 CFR 4.118, DC 7800\nbased on characteristics of disfigurement separate from gross distortion or asymmetry of an eye.\nReference\n:  For information on consideration of special monthly compensation for anatomical loss of an eye, see\nM21-1, Part VIII, Subpart iv, 4.A.4.j\n.\nV.iii.2.A.1.i\n.\nConsidering Visual Acuity in an NSC Eye When the Other Eye Is SC\nWhen visual impairment of only one eye is SC, either directly or by aggravation, consider the visual acuity of the non-service-connected (NSC) eye to be 20/40, subject to the provisions of\n38 CFR 3.383(a)\n.\nExample 1\n(Direct incurrence)\nSituation\n:\nPre-service, a Veteran had visual acuity of 20/70 in the right eye and 20/20 in the left eye, with a history of bilateral inactive chorioretinitis.\nThe Veteran developed a cataract in the left eye in service.\nPost-service, visual acuity was 20/70 in the right eye and 10/200 in the left eye.\nAt the time of the rating determination, the left eye cataract was pre-operative.\nResult\n:\nThe SC evaluation is 30 percent for the left eye cataract that was incurred in service, based on visual acuity of 10/200.\nSince the right eye is NSC, it is considered to have normal vision (20/40) for the purposes of this calculation.\nExample 2\n(Aggravation)\nSituation\n:\nPre-service, a Veteran had visual acuity of 20/50 in each eye due to scarring from an old injury.\nThe Veteran’s left eye was re-injured in combat.\nPost-service, visual acuity was 20/50 in the right eye and 10/200 in the left eye.\nResult\n:\nThe SC evaluation is 20 percent for left eye aggravation (30 percent for 10/200 (current left eye) minus 10 percent for 20/50 (left eye on entrance)).\nSince the Veteran’s right eye is NSC, it is considered to have normal vision (20/40) for the purposes of this calculation.\nReferences\n:  For more information on\nevaluating visual acuity, see\n38 CFR 4.75\nand\n38 CFR 4.79, DCs 6063 through 6066\n, and\ndetermining in-service aggravation of pre-service disability, see\n38 CFR 3.306\n, and\nM21-1, Part V, Subpart ii, 2.E\n.\nV.iii.2.A.1.j\n.\nChanges in the Eye Rating Schedule\nThe rating criteria for disabilities of the eyes have undergone historical changes.  Recent historical changes occurred on the following dates:\nMay 13, 2018, and\nDecember 10, 2008.\nNote\n:  These changes in the rating criteria\nare not considered liberalizing, and\nshould not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved.\nReference\n:  For more information on the history of changes to the rating schedule for eye disabilities, refer the\nBoard of Veterans Appeals Research Tools\nwebsite for historical\n38 CFR 4.79\n.\n2\n.\nCongenital or Developmental Defects and Refractive Error of the Eyes\nIntroduction\nThis topic contains information on congenital or developmental defects and refractive errors of the eyes, including\nexcluding congenital or developmental defects\ndefinition of refractive errors\nrefractive errors\namblyopia\n, and\nestablishing SC for unusual developments\n.\nChange Date\nFebruary 2, 2018\nV.iii.2.A.2.a\n.\nExcluding Congenital or Developmental Defects\nDefects of form or structure of the eye that are of congenital or developmental origin may\nnot\nbe considered as disabilities or SC on the basis of incurrence or aggravation beyond natural progress during service.\nThe fact that a Veteran was supplied with glasses for correcting refractive error from any of the eye defects named above is not, in itself, considered indicative of aggravation by service that would warrant compensation.\nException\n:  Malignant or pernicious myopia may be considered SC.\nV.iii.2.A.2.b\n.\nDefinition:  Refractive Errors\nRefractive errors\nare\ndue to anomalies in the shape and conformation of the eye structures, and\ngenerally of congenital or developmental origin.\nExamples\n:  Astigmatism, myopia, hyperopia, and presbyopia.\nV.iii.2.A.2.c\n.\nRefractive Errors\nThe effects of uncomplicated refractive errors must be\nexcluded\nin considering impairment of vision from the standpoint of service connection (SC) and evaluation.\nException\n:  Myopia may progress rapidly during the periods of service and lead to destructive changes, such as\nchanges in the choroid\nretinal hemorrhage, and\nretinal detachment.\nNotes\n:\nChildren are usually hyperopic at birth and subsequently become less so, or they become emmetropic, or even myopic.\nIn adults, refractive errors are generally stationary or change slowly until the stage of presbyopia, also a developmental condition.\nWhen dealing with refractive error only, if the best corrected vision on any examination by the Department of Veterans Affairs (VA) is better than prior determinations, view these prior determinations to be erroneous or at least as not representing best correction.\nReference\n:  For more information on considering SC for refractive error of the eye, see\n38 CFR  3.303(c)\n.\nV.iii.2.A.2.d\n.\nAmblyopia\nAscertain the etiology of amblyopia in each individual case since a diagnosis may refer to either developmental or acquired causes of lost visual acuity.\nV.iii.2.A.2.e\n.\nEstablishing SC for Unusual Developments\nLong-established policy permits establishment of SC for such unusual developments as choroidal degeneration, retinal hemorrhage or detachment, or rapid increase of myopia producing uncorrectable impairment of vision.\nConsider refractive error SC\nonly\nunder these unusual circumstances and when combined with uncorrectable residual visual impairment.\nNote\n:  Irregular astigmatism may be due to corneal inflammation due to injury or operation.\n3\n.\nOther Eye Conditions\nIntroduction\nThis topic contains information on specific eye conditions, including\nglaucoma\ncataracts\ndry eye syndrome\ndecision making principles - dry eye syndrome\n, and\nretinitis pigmentosa\n.\nChange Date\nMay 14, 2018\nV.iii.2.A.3.a\n.\nGlaucoma\nGlaucoma is recognized as an organic disease of the nervous system and is subject to presumptive SC under\n38 CFR 3.309(a)\n.\nConsider glaucoma, manifested to a compensable degree within one year of separation from an entitling period of service, to be SC on a presumptive basis unless there is\naffirmative evidence to the contrary, or\nevidence that a recognized cause of the condition (also known as an intercurrent cause) was incurred between the date of separation from service and the onset of the disability.\nNotes\n:\nAngle-closure glaucoma is evaluated under the General Rating Formula for Diseases of the Eye.\nWhen evaluating glaucoma, assign a minimum evaluation of 10 percent if the evidence shows that continuous medication is required.\nReference\n:  For more information on presumptive SC for organic diseases of the nervous system, see\nM21-1, Part V, Subpart iii, 12.A.1.d\n, and\nM21-1, Part V, Subpart ii, 2.B\n.\nV.iii.2.A.3.b\n.\nCataracts\n38 CFR 4.79, DC 6027\nrequires that preoperative cataracts are to be evaluated under the General Rating Formula for Diseases of the Eye.  If cataracts are postoperative in nature, evaluate under the General Rating Formula for Diseases of the Eye if a replacement lens is present (known as pseudophakia).  If there is no replacement lens, evaluate based on aphakia under\n38 CFR 4.79, DC 6029\n.\nV.iii.2.A.3.c\n.\nDry Eye Syndrome\nKeratoconjunctivitis sicca, more commonly known as\ndry eye syndrome\n, occurs when the surface of the eye becomes dry due to lack of quality tears.\nDry eye syndrome may be due to a variety of causes to include\nan underlying disease, such as diabetes mellitus or rheumatoid arthritis\nmedications, such as certain hypertensive and antidepressant medications, non-steroidal anti-inflammatory drugs, decongestants, or antihistamines, and\nenvironmental exposures such as wind, high altitude, dry air, sun, or prolonged eye concentration.\nTreatment for dry eyes may include use of over-the-counter artificial tear drops, use of prescription medications, use of special contact lenses, use of plugs to block the tear ducts through which tears drain, or even surgical procedures.\nV.iii.2.A.3.d\n.\nDecision Making Principles - Dry Eye Syndrome\nSC can be established for dry eye syndrome when it is directly incurred in, or aggravated by, service or when secondary to an SC condition.\nException\n:  Elective procedures, such as laser eye surgery (e.g., LASIK), without unusual results or additional disability attributed to elective procedures are\nnot\neligible for SC.  Dry eye syndrome is a common result of laser eye surgery, and thus would\nnot\nbe eligible for SC\nif\nthe etiology of the dry eye syndrome is due solely to an elective procedure.\nThe disability picture present with dry eye syndrome varies and, therefore, an appropriate analogous DC must be selected dependent on the symptoms noted and etiology.  Appropriate DCs may include\n38 CFR 4.79, DCs 6013, 6018, or 6025\n, depending upon the nature and symptomatology.  It may also be appropriate to evaluate as a symptom under the evaluation of the underlying condition.\nMinimal symptomatology only requiring treatment by non-prescription eye drops would typically only warrant a zero percent evaluation under\n38 CFR 4.79, DCs 6013, 6018, or 6025\nas it clearly does not approximate the criteria required for a compensable evaluation.\nReferences\n:  For more information on the\nprinciples of SC, see\n38 CFR 3.303\n38 CFR 3.306\n38 CFR 3.310\n, and\nM21-1, Part IV, Subpart ii, 2.B\n, and\nusual effects of medical and surgical treatment in service having the effect of ameliorating disease, see\n38 CFR 3.306(b)(1)\n.\nV.iii.2.A.3.e\n.\nRetinitis Pigmentosa\nSC may be awarded for diseases of congenital, developmental, or familial origin that either first manifest themselves during service or that preexist service and progress at an abnormally high rate during service so as to demonstrate aggravation.\nIf no other cause is shown for retinitis pigmentosa, consider it to be hereditary, and determine SC based on whether or not there has been aggravation of this preexisting condition during service.\nReference\n:  For more information on considering SC for developmental defects or diseases, see\nM21-1, Part V, Subpart ii, 2.E\n.\n4\n.\nExamples of Rating Decisions for Diplopia\nIntroduction\nThis topic contains examples of rating decisions for diplopia, including\nexample 1\nexample 2\n, and\nexample 3\n.\nChange Date\nAugust 3, 2011\nV.iii.2.A.4.a\n.\nExample 1\nSituation\n:  The Veteran filed an original claim for bilateral impairment of visual acuity on June 1, 2009.  VA examination reveals the best distant vision obtainable after correction is 20/200 (6/60) in the right eye and 20/70 (6/21) in the left eye.  Diplopia secondary to thyroid myopathy has been diagnosed and is within 24 degrees in the upward quadrant.  Diplopia within 24 degrees in the upward quadrant is ratable as 20/70 (6/21) under DC 6090.\nRationale\n:  Because the evaluation for diplopia is 20/70, evaluate visual acuity in the poorer eye (right) as 15/200 per\n38 CFR 4.78\n, one step poorer than it would otherwise warrant.\nCoded Conclusion\n:\n1. SC (VE INC)\n6066\nVisual impairment secondary to thyroid myopathy, bilateral, with diplopia\n40 percent from 06/01/2009\nV.iii.2.A.4.b\n.\nExample 2\nSituation\n:  The same facts as in Example 1, except the diplopia exists within 24 degrees in the downward quadrant.  Diplopia within 24 degrees in the downward quadrant is ratable as 15/200 (4.5/60) under DC 6090.\nRationale\n:  Because the evaluation for diplopia is 15/200, evaluate visual acuity in the poorer eye (right) as 10/200 per\n38 CFR 4.78\n, two steps poorer than it would otherwise warrant.\nCoded Conclusion\n:\n1. SC (VE INC)\n6066\nVisual impairment secondary to thyroid myopathy, bilateral, with diplopia\n50 percent from 06/01/2009\nV.iii.2.A.4.c\n.\nExample 3\nSituation\n:  The Veteran is SC for impairment of the visual field in the right eye secondary to trauma.  The average contraction of the visual field is to 50 degrees and is ratable equivalent to 20/50 (6/15) at 10 percent.  Diplopia has been diagnosed secondary to trauma and exists within 20 degrees in the central area.  Diplopia within 20 degrees in the central area is ratable as 5/200 (1.5/60).\nRationale\n:  Since the evaluation for diplopia is 5/200, evaluate the visual field impairment in the SC eye (right) as 20/200 per\n38 CFR 4.78\n, three steps poorer than it would otherwise warrant.\nResult\n:  Assign a 20-percent evaluation under\n38 CFR 4.79, DC 6090-6066\nfor diplopia with impairment of the visual field, right eye.  Do not assign a separate 10-percent evaluation for contraction of the visual field.\nCoded Conclusion\n:\n1. SC (VE INC)\n6090-6066\nDiplopia secondary to trauma, with impairment of visual field, right eye\n20 percent from 06/01/2009\n<--Previous Section\nNext Section-->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"> <a articleid=\"554400000014425\" articlename=\"M21-1, Part V, Subpart iii, Chapter 1, Section F - Other Musculoskeletal Considerations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014425/M21-1-Part-V-Subpart-iii-Chapter-1-Section-F-Other-Musculoskeletal-Considerations\">&lt;--Previous Section</a>  <a articleid=\"554400000014464\" articlename=\"M21-1, Part V, Subpart iii, Chapter 2, Section B - Conditions of the Auditory System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014464/M21-1-Part-V-Subpart-iii-Chapter-2-Section-B-Conditions-of-the-Auditory-System\">Next Section--&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Section</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 45px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This section contains the following topics:</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">  </span></span></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\" width=\"504\"><thead><tr><th scope=\"col\" style=\"width: 84px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 420px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 84px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1</span></span></div></td><td style=\"width: 420px; padding: 1px;\"><div><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Basic Rating Principles for Eye Conditions</span></span></a></div></td></tr><tr><td style=\"width: 84px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 420px; padding: 1px;\"><div><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Congenital and Developmental Defects and Refractive Error of the Eyes</span></span></a></div></td></tr><tr><td style=\"width: 84px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">3</span></span></div></td><td style=\"width: 420px; padding: 1px;\"><div><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Other Eye Conditions</span></span></a></div></td></tr><tr><td style=\"width: 84px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">4</span></span></div></td><td style=\"width: 420px; padding: 1px;\"><div><a href=\"#4\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Examples of Rating Decisions for Diplopia</span></span></a></div></td></tr></tbody></table><div></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/><br/> </div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">. </a>  Basic Rating Principles for Eye Conditions</span></span></h2><p class=\"ng-scope\"><br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains basic rating principles for eye conditions, including</span></span></div><ul><li><div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating visual acuity</span></span></a></div></li><li><div><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">measuring field of vision</span></span></a></div></li><li><div><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">examination requirements for diplopia</span></span></a></div></li><li><div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating diplopia with impairment of visual acuity or field</span></span></a></div></li><li><div><a href=\"#1e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">considering impairments of both visual acuity and visual field</span></span></a></div></li><li><div><a href=\"#1f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">incapacitating episodes of eye disease</span></span></a></div></li><li><div><a href=\"#1g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">citing disease or injury in the diagnosis</span></span></a></div></li><li><div><a href=\"#1h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating anatomical loss of one eye with inability to wear a prosthesis</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1i\" target=\"_self\">considering visual acuity in a non-service-connected (NSC) eye when the other eye is service-connected (SC)</a></span><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1j\" target=\"_self\">changes in the eye rating schedule</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">June 7, 2019</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.a<a id=\"1a\" name=\"1a\">.</a>  Evaluating Visual Acuity</span></span></strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Evaluate central visual acuity on the basis of corrected distance vision with central fixation, even if a central scotoma is present.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Exception</em></strong>:  Evaluate the visual acuity of the poorer eye using either its uncorrected or corrected visual acuity, whichever results in better combined visual acuity, when</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the lens required to correct distance vision in the poorer eye differs by more than three diopters from the lens required to correct distance vision in the better eye</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the difference is not due to congenital or developmental refractive error, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">either the poorer eye or both eyes are service-connected (SC).</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating eye disabilities based on visual acuity, see <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=22c1c046d70f332be0353a272e572bc6&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_176\" target=\"_blank\">38 CFR 4.76</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.b<a id=\"1b\" name=\"1b\">.</a>  Measuring Field of Vision</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The examining medical facility retains discretion in the exact method used to measure visual fields.  When visual field testing is required, the facility must use one of the following:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Goldmann Bowl kinetic perimetry</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">automatic perimetry (Humphrey Model 750, Octopus Model 101), or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">later versions of the Humphrey or Octopus machines with simulated Goldmann kinetic perimetry.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow the guidelines in <a articleid=\"554400000180516\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section B - Examination Sufficiency for Specific Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180516/M21-1-Part-IV-Subpart-i-Chapter-3-Section-B-Examination-Sufficiency-for-Specific-Disabilities\">M21-1, Part IV, Subpart i, 3.B.1.a</a> to determine when an examination report must contain visual field measurements.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Results from visual field testing may be reported in chart or table format.  Inclusion of the Goldmann chart or equivalent charting is not a requirement in any circumstance.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">visual field standards, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.4_177&amp;rgn=div8\" target=\"_blank\">38 CFR 4.77</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">examinations for visual impairment and specifically visual field, see <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=17e2f0caa776ea0389871f8d58e7c40a&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_175\" target=\"_blank\">38 CFR 4.77</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.c<a id=\"1c\" name=\"1c\">.</a>  Examination Requirements for Diplopia</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=19d4b5fd63074bfe80505a566e32bbeb&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_178\" target=\"_blank\">38 CFR 4.78</a> requires use of Goldmann Bowl kinetic perimeter testing or the Tangent Screen for examination of muscle function.  The examiner must document the results of muscle function testing by identifying the quadrant(s) and range(s) of degrees in which diplopia exists.  Documentation on a Goldmann Perimeter Chart is <em>not</em> required but is acceptable. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A diagnosis of diplopia that reflects the disease or injury that is the cause of the diplopia must be of record.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.d<a id=\"1d\" name=\"1d\">.</a>  Evaluating Diplopia With Impairment of Visual Acuity or Field</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When the affected field with diplopia extends beyond more than one quadrant or range of degrees, evaluate diplopia based on the quadrant and degree range that provides the higher (or highest) evaluation.  When diplopia exists in two separate areas of the same eye, increase the equivalent visual acuity under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, diagnostic code (DC) 6090</a> to the next poorer level of visual acuity, but not to exceed 5/200.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow the steps in the table below when assigning an evaluation to visual impairment when a claimant has both</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">diplopia, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">a ratable impairment of visual acuity or loss of visual field in either eye.</span></span></div></li></ul><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 describes the actions to take when evaluating diplopia together with impairment of visual acuity or visual field.  Step 2 contains an additional table.\"><thead><tr><th scope=\"col\" style=\"width: 59px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Step</strong></span></span></div></th><th scope=\"col\" style=\"width: 445px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Action</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 59px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1</span></span></div></td><td style=\"width: 445px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Assign a level of visual acuity for diplopia for only one eye under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6090</a>.</span></span></div></td></tr><tr><td style=\"width: 59px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">2</span></span></div></td><td style=\"width: 445px; padding: 1px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Follow the instructions in the table below. </span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This is an If-Then table.  Column 1 provides the criteria and column 2 provides instruction for assigning a level of corrected visual acuity.\" width=\"429\"><thead><tr><th scope=\"col\" style=\"width: 179px; padding: 1px;\"><div align=\"left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>If the visual acuity level assignable for diplopia is …</strong></span></span></div></th><th scope=\"col\" style=\"width: 250px; padding: 1px;\"><div align=\"left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Then assign a level of corrected visual acuity for the poorer eye (or affected eye, if only one is SC) that is …</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 179px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">20/70 or 20/100</span></span></div></td><td style=\"width: 250px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">one step poorer than it would otherwise warrant, not to exceed 5/200.</span></span></div></td></tr><tr><td style=\"width: 179px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">20/200 or 15/200</span></span></div></td><td style=\"width: 250px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">two steps poorer than it would otherwise warrant, not to exceed 5/200.</span></span></div></td></tr><tr><td style=\"width: 179px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">5/200</span></span></div></td><td style=\"width: 250px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">three steps poorer than it would otherwise warrant, not to exceed 5/200.</span></span></div></td></tr></tbody></table></div></td></tr><tr><td style=\"width: 59px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></div></td><td style=\"width: 445px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Determine the evaluation for visual impairment under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6065 or 6066</a> by using the</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">adjusted visual acuity of the poorer eye (or affected eye, if only one is SC), and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">corrected visual acuity for the better eye (or visual acuity of 20/40 for the other eye, if only one eye is SC).</span></span></div></li></ul></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em> </em></strong></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The Veteran has an SC evaluation for diplopia.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Diplopia in both eyes is in the 31 to 40 degree range of upward vision and in the 31 to 40 degree range of lateral vision.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The diplopia in the upward vision is equivalent to visual acuity of 20/40, while the diplopia in the lateral vision is equivalent to visual acuity of 20/70.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Based on <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=19d4b5fd63074bfe80505a566e32bbeb&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_178\" target=\"_blank\">38 CFR 4.78(b)(2) and (3)</a>, the overall equivalent visual acuity for diplopia is 20/100, which is one step poorer than the diplopia (in this case, the lateral) that provides the higher evaluation.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The overall evaluation for diplopia is, therefore, 10 percent, based on visual acuity of 20/100 for one eye and 20/40 for the other eye (diplopia is only taken into consideration for one eye).</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  Diplopia that is occasional or that is correctable with corrective lenses is evaluated at zero percent.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For examples of rating decisions for diplopia, see <a href=\"#4\" target=\"_self\">M21-1, Part V, Subpart iii, 2.A.4</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.e<a id=\"1e\" name=\"1e\">.</a>  Considering Impairments of Both Visual Acuity and Visual Field</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When there are impairments of both visual acuity and visual field</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">determine for each eye the percentage evaluation for visual acuity and for visual field loss (expressed as a level of visual acuity under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6080</a>), and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">combine the evaluations under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.4_125&amp;rgn=div8\" target=\"_blank\">38 CFR 4.25</a>. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The combined evaluation for visual impairment can then be combined with any other disabilities that are present.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Situation</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Corrected visual acuity is 20/40 in the right eye and 20/70 in the left eye, warranting a 10-percent evaluation.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Visual field loss in right eye is remaining field 38 degrees (equivalent to visual acuity 20/70) and loss in left eye is remaining field 28 degrees (equivalent to visual acuity 20/100), warranting a 30-percent evaluation. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  Under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.4_125&amp;rgn=div8\" target=\"_blank\">38 CFR 4.25</a>, combine the 30-percent evaluation for visual field loss with the 10-percent evaluation for visual acuity, which results in a 40-percent combined evaluation for bilateral visual impairment.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.2.A.1.f<a id=\"1f\" name=\"1f\">.</a>  Incapacitating Episodes of Eye Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">An incapacitating episode, for the purpose of evaluating diseases of the eye, is a situation in which symptoms are severe enough to require a clinic visit to a provider specifically for treatment purposes. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A clinic visit for diagnostic, monitoring, or screening purposes is not sufficient to satisfy the criteria for a clinic visit for treatment purposes.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The definition of incapacitating episode was updated effective with the May 13, 2018, revision to <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=d7c96f0fcb5a100e480ddefb72def70e&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79</a>.  This and other changes made in that update were not liberalizing changes. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on incapacitating episodes of diseases of the eye, as well as examples of treatment sufficient to meet the criteria for incapacitating episodes, see <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=d7c96f0fcb5a100e480ddefb72def70e&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79</a>, <em>General Rating Formula for Diseases of the Eye</em>, Notes 1 and 2.</span></span></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.g<a id=\"1g\" name=\"1g\">.</a>  Citing Disease or Injury in the Diagnosis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Cite the actual disease, injury, or other basic condition as the diagnosis, rather than a mere citation of impaired visual acuity, field of vision, or motor efficiency.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  Actual pathology, other than refractive error, is required to support </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">impairment of visual acuity.  Impaired field of vision and impaired motor field function must be supported by actual appropriate pathology.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.h<a id=\"1h\" name=\"1h\">.</a>  Evaluating Anatomical Loss of One Eye With Inability to Wear a Prosthesis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When the evidence shows anatomical loss of one eye together with inability to wear a prosthesis, increase the evaluation for visual acuity under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c4e7d0356721b57e78355df0a68ce8b5&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6063</a> by 10 percent.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The maximum evaluation for visual impairment of both eyes will not exceed 100 percent.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Assignment of the 10-percent increase under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c4e7d0356721b57e78355df0a68ce8b5&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6063</a> precludes an evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c4e7d0356721b57e78355df0a68ce8b5&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a> based on gross distortion or asymmetry of an eye.  A separate evaluation may be assigned under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c4e7d0356721b57e78355df0a68ce8b5&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a> based on characteristics of disfigurement separate from gross distortion or asymmetry of an eye.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For information on consideration of special monthly compensation for anatomical loss of an eye, see <a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4.j</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.1.i<a id=\"1i\" name=\"1i\">.</a>  Considering Visual Acuity in an NSC Eye When the Other Eye Is SC</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When visual impairment of only one eye is SC, either directly or by aggravation, consider the visual acuity of the non-service-connected (NSC) eye to be 20/40, subject to the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.3_1383&amp;rgn=div8\" target=\"_blank\">38 CFR 3.383(a)</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example 1</em></strong> (Direct incurrence)</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Situation</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Pre-service, a Veteran had visual acuity of 20/70 in the right eye and 20/20 in the left eye, with a history of bilateral inactive chorioretinitis.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The Veteran developed a cataract in the left eye in service. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Post-service, visual acuity was 20/70 in the right eye and 10/200 in the left eye.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">At the time of the rating determination, the left eye cataract was pre-operative. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The SC evaluation is 30 percent for the left eye cataract that was incurred in service, based on visual acuity of 10/200.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Since the right eye is NSC, it is considered to have normal vision (20/40) for the purposes of this calculation.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example 2</em></strong> (Aggravation)</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Situation</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Pre-service, a Veteran had visual acuity of 20/50 in each eye due to scarring from an old injury.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The Veteran’s left eye was re-injured in combat. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Post-service, visual acuity was 20/50 in the right eye and 10/200 in the left eye. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The SC evaluation is 20 percent for left eye aggravation (30 percent for 10/200 (current left eye) minus 10 percent for 20/50 (left eye on entrance)).</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Since the Veteran’s right eye is NSC, it is considered to have normal vision (20/40) for the purposes of this calculation.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating visual acuity, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.4_175&amp;rgn=div8\" target=\"_blank\">38 CFR 4.75</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DCs 6063 through 6066</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">determining in-service aggravation of pre-service disability, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e97bb2a474325f8eab5ea7a335774c6&amp;node=se38.1.3_1306&amp;rgn=div8\" target=\"_blank\">38 CFR 3.306</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180485\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section E - Service Connection (SC) for Congenital, Developmental, or Hereditary Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180485/M21-1-Part-V-Subpart-ii-Chapter-2-Section-E-Service-Connection-SC-for-Congenital-Developmental-or-Hereditary-Disorders\">M21-1, Part V, Subpart ii, 2.E</a>.</span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.2.A.1.j<a id=\"1j\" name=\"1j\">.</a>  Changes in the Eye Rating Schedule </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The rating criteria for disabilities of the eyes have undergone historical changes.  Recent historical changes occurred on the following dates:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May 13, 2018, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">December 10, 2008.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  These changes in the rating criteria</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">are not considered liberalizing, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">should not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on the history of changes to the rating schedule for eye disabilities, refer the <a href=\"http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3aproject=lsa-bva-counsel-judge-project&amp;v%3asources=lsa-bva-citator-regulation-collection&amp;frontpage=1&amp;v%3aframe=form&amp;\" target=\"_blank\">Board of Veterans Appeals Research Tools</a> website for historical <a href=\"http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3Asources=lsa-bva-citator-regulation-collection&amp;v%3Aproject=lsa-bva-counsel-judge-project&amp;lnquery=38+CFR+4.79&amp;lnfilters=&amp;chkbxfilters=&amp;query=%28%2238+cfr+4.79%22%29&amp;querytype=boolean\" target=\"_blank\">38 CFR 4.79</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\"></div><h2 class=\"ng-scope\"> <span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Congenital or Developmental Defects and Refractive Error of the Eyes</span></span></h2><p class=\"ng-scope\"></p><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Introduction</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information on congenital or developmental defects and refractive errors of the eyes, including<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">excluding congenital or developmental defects</span></span></a></div></li><li><div><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">definition of refractive errors</span></span></a></div></li><li><div><a href=\"#2c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">refractive errors</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2d\" target=\"_self\">amblyopia</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2e\" target=\"_self\">establishing SC for unusual developments</a>. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div> <span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">February 2, 2018</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.2.a<a id=\"2a\" name=\"2a\">.</a>  Excluding Congenital or Developmental Defects</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Defects of form or structure of the eye that are of congenital or developmental origin may <em>not</em> be considered as disabilities or SC on the basis of incurrence or aggravation beyond natural progress during service.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The fact that a Veteran was supplied with glasses for correcting refractive error from any of the eye defects named above is not, in itself, considered indicative of aggravation by service that would warrant compensation.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Exception</em></strong>:  Malignant or pernicious myopia may be considered SC.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.2.b<a id=\"2b\" name=\"2b\">.</a>  Definition:  Refractive Errors</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Refractive errors</em></strong> are</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">due to anomalies in the shape and conformation of the eye structures, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">generally of congenital or developmental origin.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Examples</em></strong>:  Astigmatism, myopia, hyperopia, and presbyopia.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.2.c<a id=\"2c\" name=\"2c\">.</a>  Refractive Errors</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The effects of uncomplicated refractive errors must be <em>excluded</em> in considering impairment of vision from the standpoint of service connection (SC) and evaluation.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Exception</em></strong>:  Myopia may progress rapidly during the periods of service and lead to destructive changes, such as</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">changes in the choroid</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">retinal hemorrhage, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">retinal detachment.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Children are usually hyperopic at birth and subsequently become less so, or they become emmetropic, or even myopic.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In adults, refractive errors are generally stationary or change slowly until the stage of presbyopia, also a developmental condition.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When dealing with refractive error only, if the best corrected vision on any examination by the Department of Veterans Affairs (VA) is better than prior determinations, view these prior determinations to be erroneous or at least as not representing best correction.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on considering SC for refractive error of the eye, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR  3.303(c)</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.2.d<a id=\"2d\" name=\"2d\">.</a>  Amblyopia</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Ascertain the etiology of amblyopia in each individual case since a diagnosis may refer to either developmental or acquired causes of lost visual acuity.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.2.e<a id=\"2e\" name=\"2e\">.</a>  Establishing SC for Unusual Developments </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Long-established policy permits establishment of SC for such unusual developments as choroidal degeneration, retinal hemorrhage or detachment, or rapid increase of myopia producing uncorrectable impairment of vision. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider refractive error SC <em>only</em> under these unusual circumstances and when combined with uncorrectable residual visual impairment.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  Irregular astigmatism may be due to corneal inflammation due to injury or operation.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><p class=\"ng-scope\"><br/> </p><h2 class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">3<a id=\"3\" name=\"3\">.</a>  Other Eye Conditions</span></span></strong></h2><p class=\"ng-scope\"><br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on specific eye conditions, including</span></span></div><ul><li><div><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">glaucoma</span></span></a></div></li><li><div><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">cataracts</span></span></a></div></li><li><div><a href=\"#3c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">dry eye syndrome</span></span></a></div></li><li><div><a href=\"#3d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">decision making principles - dry eye syndrome</span></span></a>, and</div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3e\" target=\"_self\">retinitis pigmentosa</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">May 14, 2018</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.3.a<a id=\"3a\" name=\"3a\">.</a>  Glaucoma</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Glaucoma is recognized as an organic disease of the nervous system and is subject to presumptive SC under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e97bb2a474325f8eab5ea7a335774c6&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(a)</a>. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Consider glaucoma, manifested to a compensable degree within one year of separation from an entitling period of service, to be SC on a presumptive basis unless there is</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">affirmative evidence to the contrary, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evidence that a recognized cause of the condition (also known as an intercurrent cause) was incurred between the date of separation from service and the onset of the disability.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Angle-closure glaucoma is evaluated under the General Rating Formula for Diseases of the Eye.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When evaluating glaucoma, assign a minimum evaluation of 10 percent if the evidence shows that continuous medication is required.</span></span></div></li></ul><div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on presumptive SC for organic diseases of the nervous system, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180519\" articlename=\"M21-1, Part V, Subpart iii, Chapter 12, Section A - Neurological Conditions and Convulsive Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180519/M21-1-Part-V-Subpart-iii-Chapter-12-Section-A-Neurological-Conditions-and-Convulsive-Disorders\">M21-1, Part V, Subpart iii, 12.A.1.d</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180482\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section B - Presumptive Service Connection (SC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180482/M21-1-Part-V-Subpart-ii-Chapter-2-Section-B-Presumptive-Service-Connection-SC\">M21-1, Part V, Subpart ii, 2.B</a>.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.3.b<a id=\"3b\" name=\"3b\">.</a>  Cataracts</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6027</a> requires that preoperative cataracts are to be evaluated under the General Rating Formula for Diseases of the Eye.  If cataracts are postoperative in nature, evaluate under the General Rating Formula for Diseases of the Eye if a replacement lens is present (known as pseudophakia).  If there is no replacement lens, evaluate based on aphakia under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6029</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.3.c<a id=\"3c\" name=\"3c\">.</a>  Dry Eye Syndrome </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Keratoconjunctivitis sicca, more commonly known as <strong><em>dry eye syndrome</em></strong>, occurs when the surface of the eye becomes dry due to lack of quality tears. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Dry eye syndrome may be due to a variety of causes to include</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">an underlying disease, such as diabetes mellitus or rheumatoid arthritis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">medications, such as certain hypertensive and antidepressant medications, non-steroidal anti-inflammatory drugs, decongestants, or antihistamines, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">environmental exposures such as wind, high altitude, dry air, sun, or prolonged eye concentration. </span></span></div></li></ul><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Treatment for dry eyes may include use of over-the-counter artificial tear drops, use of prescription medications, use of special contact lenses, use of plugs to block the tear ducts through which tears drain, or even surgical procedures.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.3.d<a id=\"3d\" name=\"3d\">.</a>  Decision Making Principles - Dry Eye Syndrome</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC can be established for dry eye syndrome when it is directly incurred in, or aggravated by, service or when secondary to an SC condition.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Exception</em></strong>:  Elective procedures, such as laser eye surgery (e.g., LASIK), without unusual results or additional disability attributed to elective procedures are <strong><em>not</em></strong> eligible for SC.  Dry eye syndrome is a common result of laser eye surgery, and thus would <strong><em>not</em></strong> be eligible for SC <strong><em>if</em></strong> the etiology of the dry eye syndrome is due solely to an elective procedure.  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The disability picture present with dry eye syndrome varies and, therefore, an appropriate analogous DC must be selected dependent on the symptoms noted and etiology.  Appropriate DCs may include <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DCs 6013, 6018, or 6025</a>, depending upon the nature and symptomatology.  It may also be appropriate to evaluate as a symptom under the evaluation of the underlying condition.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Minimal symptomatology only requiring treatment by non-prescription eye drops would typically only warrant a zero percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DCs 6013, 6018, or 6025</a> as it clearly does not approximate the criteria required for a compensable evaluation.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on the</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">principles of SC, see </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=a16b7e1503e02afb95bd9ec3d04c5bc8&amp;mc=true&amp;r=SECTION&amp;n=se38.1.3_1303\" target=\"_blank\">38 CFR 3.303</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=47e90bac2cbb952ebc5062d94da358e6&amp;mc=true&amp;node=se38.1.3_1306&amp;rgn=div8\" target=\"_blank\">38 CFR 3.306</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=dee58467fac637e7841bffc2febb2fa4&amp;mc=true&amp;r=SECTION&amp;n=se38.1.3_1310\" target=\"_blank\">38 CFR 3.310</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014553\" articlename=\"M21-1, Part IV, Subpart ii, Chapter 2, Section B - Failure to Report for Review Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014553/M21-1-Part-IV-Subpart-ii-Chapter-2-Section-B-Failure-to-Report-for-Review-Examinations\">M21-1, Part IV, Subpart ii, 2.B</a>, and</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">usual effects of medical and surgical treatment in service having the effect of ameliorating disease, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=47e90bac2cbb952ebc5062d94da358e6&amp;mc=true&amp;node=se38.1.3_1306&amp;rgn=div8\" target=\"_blank\">38 CFR 3.306(b)(1)</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.3.e<a id=\"3e\" name=\"3e\">.</a>  Retinitis Pigmentosa</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC may be awarded for diseases of congenital, developmental, or familial origin that either first manifest themselves during service or that preexist service and progress at an abnormally high rate during service so as to demonstrate aggravation.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If no other cause is shown for retinitis pigmentosa, consider it to be hereditary, and determine SC based on whether or not there has been aggravation of this preexisting condition during service.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em><strong>Reference</strong></em>:  For more information on considering SC for developmental defects or diseases, see <a articleid=\"554400000180485\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section E - Service Connection (SC) for Congenital, Developmental, or Hereditary Disorders\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180485/M21-1-Part-V-Subpart-ii-Chapter-2-Section-E-Service-Connection-SC-for-Congenital-Developmental-or-Hereditary-Disorders\">M21-1, Part V, Subpart ii, 2.E</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\"> <br/> </p><h2 class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">4<a id=\"4\" name=\"4\">.</a>   Examples of Rating Decisions for Diplopia</span></span></strong></h2><p class=\"ng-scope\"><br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains examples of rating decisions for diplopia, including</span></span></div><ul><li><div><a href=\"#4a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">example 1</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#4b\" target=\"_self\">example 2</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#4c\" target=\"_self\">example 3</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">August 3, 2011</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.4.a<a id=\"4a\" name=\"4a\">.</a>  Example 1</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Situation</em></strong>:  The Veteran filed an original claim for bilateral impairment of visual acuity on June 1, 2009.  VA examination reveals the best distant vision obtainable after correction is 20/200 (6/60) in the right eye and 20/70 (6/21) in the left eye.  Diplopia secondary to thyroid myopathy has been diagnosed and is within 24 degrees in the upward quadrant.  Diplopia within 24 degrees in the upward quadrant is ratable as 20/70 (6/21) under DC 6090.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Rationale</em></strong>:  Because the evaluation for diplopia is 20/70, evaluate visual acuity in the poorer eye (right) as 15/200 per <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&amp;node=pt38.1.4&amp;rgn=div5#se38.1.4_178\" target=\"_blank\">38 CFR 4.78</a>, one step poorer than it would otherwise warrant.  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">  </span></span></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"Example 1 coded conclusion. \"><tbody><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div align=\"left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Coded Conclusion</em></strong>:</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div></td></tr><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1. SC (VE INC)</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div></td></tr><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">6066</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Visual impairment secondary to thyroid myopathy, bilateral, with diplopia</span></span></div></td></tr><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">40 percent from 06/01/2009</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div></td></tr></tbody></table><div></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.4.b<a id=\"4b\" name=\"4b\">.</a>  Example 2</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Situation</em></strong>:  The same facts as in Example 1, except the diplopia exists within 24 degrees in the downward quadrant.  Diplopia within 24 degrees in the downward quadrant is ratable as 15/200 (4.5/60) under DC 6090. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Rationale</em></strong>:  Because the evaluation for diplopia is 15/200, evaluate visual acuity in the poorer eye (right) as 10/200 per <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=ea5f459a05583259ee4e4223f7300b71&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_178\" target=\"_blank\">38 CFR 4.78</a>, two steps poorer than it would otherwise warrant.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">  </span></span></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"Example 2 coded conclusion. \"><tbody><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div align=\"left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Coded Conclusion</em></strong>:</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div></td></tr><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1. SC (VE INC)</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div></td></tr><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">6066</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Visual impairment secondary to thyroid myopathy, bilateral, with diplopia</span></span></div></td></tr><tr><td style=\"height: 18px; width: 191px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">50 percent from 06/01/2009</span></span></div></td><td style=\"height: 18px; width: 312px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div></td></tr></tbody></table><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.2.A.4.c<a id=\"4c\" name=\"4c\">.</a>  Example 3</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Situation</em></strong>:  The Veteran is SC for impairment of the visual field in the right eye secondary to trauma.  The average contraction of the visual field is to 50 degrees and is ratable equivalent to 20/50 (6/15) at 10 percent.  Diplopia has been diagnosed secondary to trauma and exists within 20 degrees in the central area.  Diplopia within 20 degrees in the central area is ratable as 5/200 (1.5/60). </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Rationale</em></strong>:  Since the evaluation for diplopia is 5/200, evaluate the visual field impairment in the SC eye (right) as 20/200 per <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=ea5f459a05583259ee4e4223f7300b71&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_178\" target=\"_blank\">38 CFR 4.78</a>, three steps poorer than it would otherwise warrant. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  Assign a 20-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2bb055915eba25b3cbf844a90b790fd1&amp;mc=true&amp;node=se38.1.4_179&amp;rgn=div8\" target=\"_blank\">38 CFR 4.79, DC 6090-6066</a> for diplopia with impairment of the visual field, right eye.  Do not assign a separate 10-percent evaluation for contraction of the visual field.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">  </span></span></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"Example 3 coded conclusion. \"><tbody><tr><td style=\"height: 18px; width: 179px; padding: 0px;\"><div align=\"left\"><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em>Coded Conclusion</em></span></span></strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">:</span></span></div></td><td style=\"height: 18px; width: 324px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div></td></tr><tr><td style=\"height: 18px; width: 179px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1. SC (VE INC)</span></span></div></td><td style=\"height: 18px; width: 324px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div></td></tr><tr><td style=\"height: 18px; width: 179px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">6090-6066</span></span></div></td><td style=\"height: 18px; width: 324px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Diplopia secondary to trauma, with impairment of visual field, right eye</span></span></div></td></tr><tr><td style=\"height: 18px; width: 179px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">20 percent from 06/01/2009</span></span></div></td><td style=\"height: 18px; width: 324px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div></td></tr></tbody></table><div></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"> <a articleid=\"554400000014425\" articlename=\"M21-1, Part V, Subpart iii, Chapter 1, Section F - Other Musculoskeletal Considerations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014425/M21-1-Part-V-Subpart-iii-Chapter-1-Section-F-Other-Musculoskeletal-Considerations\">&lt;--Previous Section</a>  <a articleid=\"554400000014464\" articlename=\"M21-1, Part V, Subpart iii, Chapter 2, Section B - Conditions of the Auditory System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014464/M21-1-Part-V-Subpart-iii-Chapter-2-Section-B-Conditions-of-the-Auditory-System\">Next Section--&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3Asources=lsa-bva-citator-regulation-collection&v%3Aproject=lsa-bva-counsel-judge-project&lnquery=38+CFR+4.79&lnfilters=&chkbxfilters=&query=%28%2238+cfr+4.79%22%29&querytype=boolean",
    "http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3aproject=lsa-bva-counsel-judge-project&v%3asources=lsa-bva-citator-regulation-collection&frontpage=1&v%3aframe=form&",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=17e2f0caa776ea0389871f8d58e7c40a&mc=true&r=SECTION&n=se38.1.4_175",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=19d4b5fd63074bfe80505a566e32bbeb&mc=true&r=SECTION&n=se38.1.4_178",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=22c1c046d70f332be0353a272e572bc6&mc=true&r=SECTION&n=se38.1.4_176",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=a16b7e1503e02afb95bd9ec3d04c5bc8&mc=true&r=SECTION&n=se38.1.3_1303",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=dee58467fac637e7841bffc2febb2fa4&mc=true&r=SECTION&n=se38.1.3_1310",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=ea5f459a05583259ee4e4223f7300b71&mc=true&r=SECTION&n=se38.1.4_178",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2bb055915eba25b3cbf844a90b790fd1&mc=true&node=se38.1.4_179&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=pt38.1.4&rgn=div5#se38.1.4_178",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=se38.1.3_1303&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=se38.1.3_1383&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=se38.1.4_125&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=se38.1.4_175&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=se38.1.4_177&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2d94638b61518c7911ce188979c6b4bf&node=se38.1.4_179&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=47e90bac2cbb952ebc5062d94da358e6&mc=true&node=se38.1.3_1306&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=5e97bb2a474325f8eab5ea7a335774c6&node=se38.1.3_1306&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=5e97bb2a474325f8eab5ea7a335774c6&node=se38.1.3_1309&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=5e9be5ae67db124ca3e516b56bc6efaf&mc=true&node=se38.1.4_179&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=c4e7d0356721b57e78355df0a68ce8b5&mc=true&node=se38.1.4_1118&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=c4e7d0356721b57e78355df0a68ce8b5&mc=true&node=se38.1.4_179&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=d7c96f0fcb5a100e480ddefb72def70e&mc=true&node=se38.1.4_179&rgn=div8"
  ],
  "scraped_at": "2025-06-16T22:44:02.345462",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014464/M21-1-Part-V-Subpart-iii-Chapter-2-Section-B-Conditions-of-the-Auditory-System"
}